We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Trial Sponsors Urged to Get Early U.S. FDA Approval of PROs
Trial Sponsors Urged to Get Early U.S. FDA Approval of PROs
December 9, 2011
Drug trial sponsors developing patient-reported outcome (PRO) measures should seek U.S. Food and Drug Administration (FDA) qualification for them prior to engaging in clinical trials, and should use the measures to gauge quality of life, Janet Woodcock, director of the U.S. Center for Drug Evaluation and Research, advises.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor